Cvfg LLC Makes New Investment in Elevance Health, Inc. (NYSE:ELV)

Cvfg LLC purchased a new position in Elevance Health, Inc. (NYSE:ELV - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 1,473 shares of the company's stock, valued at approximately $543,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Cypress Wealth Services LLC lifted its position in Elevance Health by 3.5% in the third quarter. Cypress Wealth Services LLC now owns 679 shares of the company's stock worth $353,000 after purchasing an additional 23 shares during the period. Atomi Financial Group Inc. lifted its holdings in shares of Elevance Health by 4.2% during the 3rd quarter. Atomi Financial Group Inc. now owns 615 shares of the company's stock worth $320,000 after acquiring an additional 25 shares during the period. Lifeworks Advisors LLC lifted its holdings in shares of Elevance Health by 2.5% during the 3rd quarter. Lifeworks Advisors LLC now owns 1,037 shares of the company's stock worth $539,000 after acquiring an additional 25 shares during the period. Catalyst Financial Partners LLC boosted its position in shares of Elevance Health by 2.9% during the 3rd quarter. Catalyst Financial Partners LLC now owns 918 shares of the company's stock valued at $477,000 after acquiring an additional 26 shares in the last quarter. Finally, Fullcircle Wealth LLC increased its stake in Elevance Health by 1.5% in the third quarter. Fullcircle Wealth LLC now owns 1,743 shares of the company's stock valued at $906,000 after acquiring an additional 26 shares during the period. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ELV has been the topic of a number of recent research reports. Wells Fargo & Company decreased their price objective on Elevance Health from $593.00 to $495.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. Truist Financial decreased their price target on Elevance Health from $520.00 to $480.00 and set a "buy" rating on the stock in a research note on Monday, January 6th. TD Cowen dropped their price objective on Elevance Health from $589.00 to $484.00 and set a "buy" rating for the company in a research note on Monday, October 21st. StockNews.com upgraded shares of Elevance Health from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Mizuho dropped their target price on shares of Elevance Health from $585.00 to $505.00 and set an "outperform" rating for the company in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $536.53.

Elevance Health Trading Down 0.3 %

ELV stock traded down $1.00 during trading on Friday, hitting $384.26. The company had a trading volume of 2,696,400 shares, compared to its average volume of 1,744,120. The firm has a 50-day moving average price of $388.79 and a 200-day moving average price of $468.15. Elevance Health, Inc. has a 12 month low of $362.21 and a 12 month high of $567.26. The company has a quick ratio of 1.50, a current ratio of 1.50 and a debt-to-equity ratio of 0.56. The stock has a market cap of $89.12 billion, a price-to-earnings ratio of 14.01, a PEG ratio of 1.08 and a beta of 0.84.

Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings results on Thursday, October 17th. The company reported $8.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $9.66 by ($1.29). The firm had revenue of $44.72 billion for the quarter, compared to analyst estimates of $43.47 billion. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. The company's revenue was up 5.3% compared to the same quarter last year. During the same period last year, the company earned $8.99 EPS. As a group, analysts predict that Elevance Health, Inc. will post 32.96 earnings per share for the current year.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.